{"id":"W7117296119","doi":"10.1016/j.iotech.2025.101450","title":"251P Final results of the FAK-PD1 phase I/IIA study of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"NIH Clinical Center; University of California, San Diego; Genentech; Sierra Oncology; Ipsen; Servier; Weill Cornell Medical College; National Institute for Health and Care Research; Seagen; Sidney Kimmel Comprehensive Cancer Center; Pfizer; Moderna; NuCana; Incyte; Boston Pharmaceuticals; Cancer Research UK; Verastem Oncology; Amgen; Barbara Ann Karmanos Cancer Institute; BeiGene; Les Laboratories Pierre Fabre; Moffitt Cancer Center; Sanofi; Exelixis; Astellas Pharma; Eisai; Thomas Jefferson University; Johns Hopkins University; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Phase (matter); Cancer; Solid tumor; Cytotoxicity","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005678727,0.0002250549,0.0008458476,0.001215705,0.00009667034,0.000004264208,0.0003087383,0.0005265932,0.00003334193],"category_scores_gemma":[0.001533569,0.0001828225,0.00008111332,0.001548573,0.000947697,0.00005108942,0.0006470519,0.0009341067,0.000004025514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002540742,"about_ca_system_score_gemma":0.0005161129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001517608,"about_ca_topic_score_gemma":0.0003313543,"domain_scores_codex":[0.9974751,0.0002973048,0.001002712,0.0005088039,0.0002714091,0.0004446878],"domain_scores_gemma":[0.9980329,0.0003681613,0.0003880251,0.0008860187,0.0002827096,0.00004213233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01015936,0.004452121,0.01246272,0.0001243534,0.0001274474,0.000270594,0.000714033,0.00002928047,0.9100993,0.0003791927,0.0004020024,0.06077955],"study_design_scores_gemma":[0.07735017,0.01485071,0.079034,0.0004736629,0.0001922603,0.0003840043,0.008041905,0.0002365061,0.8131578,0.001467156,0.004561056,0.000250787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902028,0.0006929335,0.0000346344,0.004205914,0.0001685643,0.00158331,0.00001788273,0.00006724778,0.003026683],"genre_scores_gemma":[0.9986566,0.0002233197,0.0002527495,0.0001017371,0.000008718085,0.0001347147,0.00001168222,0.00001941969,0.0005910001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09694156,"threshold_uncertainty_score":0.7455285,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02047705227220095,"score_gpt":0.385868474467102,"score_spread":0.3653914221949011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}